Downstream purification continues to pressure the biopharmaceutical manufacturing industry from a capacity standpoint, with recent increases in upstream yield and titers overcoming the relatively slow ...

With multiple, complex chromatographic purification, buffer exchange, and viral inactivation steps, downstream processing of monoclonal antibodies (mAbs) remains the major bottleneck in ...

Gene therapy has emerged as a cutting-edge modality with transformative potential for treating a broad range of genetic disorders. Despite significant advancements, the purification and separation of ...

ArgusEye, announced the introduction of the AugaOne™ sensor system. AugaOne is the first product in the Company’s sensor system platform, Auga™, and is tailored to accelerate downstream monoclonal ...

New Laboratories Have Potential to Support an Additional $20 Million in Annual Process Development Revenue, Doubling Current Mammalian Cell Process Development Capacity Expansion to Cost Approximately ...

Resolving operational bottlenecks makes mAb manufacturing more efficient. Traditional biologics, which are predominantly monoclonal antibodies (mAbs), are continuing to see strong market demand, and ...

TUSTIN, Calif. and CARLSBAD, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization ...